Do you want to read an article? Please log in or register.
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
Migraine and Headache
RECOMMENDED
Related content
RECOMMENDED
Migraine and Headache
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Cephalalgia.
Dodick DW, Goadsby PJ, Lucas C, Jensen R, Bardos JN, Martinez JM, Zhou C, Aurora SK, Yang JY, Conley RR, Oakes T
doi: 10.1177/0333102420905321.
RECOMMENDED
Migraine and Headache
Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Headache
Smitherman TA, Tietjen GE, Schuh K, Skljarevski V, Lipsius S, D'Souza DN, Pearlman EM
doi: 10.1111/head.13970
RECOMMENDED
Migraine and Headache
Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial
Brain.
Pijpers JA, Kies DA, Louter MA, van Zwet EW, Ferrari MD, Terwindt GM
doi: 10.1093/
RECOMMENDED
Migraine and Headache
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
★ 2
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 2
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
doi: 10.1177/0333102420905132.
Migraine and Headache
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine
Cephalalgia
Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, Jedynak J, Dong Y, Pearlman EM
doi: 10.1177/0333102420966658
Migraine and Headache
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
Lancet Neurol.
Mulleners WM, Kim BK, Láinez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC
doi: 10.1016/S1474-4422(20)30279-9.
Migraine and Headache
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study
Headache
Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD
doi: 10.1111/head.14138
RECOMMENDED
Migraine and Headache
Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
doi: 10.1177/0333102419835459.
RECOMMENDED
Anxiety and DepressionBipolar Disorder
Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study
Am J Psychiatry.
Earley W, Victoria Burgess M, Rekeda L, Dickinson R, Szatmári B, Németh G, McIntyre RS, Sachs GS, Yatham LN
doi: 10.1176/appi.ajp.